Opinion|Videos|October 18, 2024
Defining Treatment Success with Oral Treatments in Patients with Plaque Psoriasis
Author(s)E. James Song, MD, FAAD
E. James Song, MD, FAAD, provides key takeaways on the treatment of patients with plaque psoriasis, highlighting ways to define treatment success and the effect of adverse events on long-term treatment choices.
Advertisement
Episodes in this series
Advertisement
Related to this article
At 2 years, 70% of patients on oral icotrokinra for scalp, genital, or hand/foot psoriasis had clear or almost clear skin, with no new safety signals.
Phase 3 LATITUDE Atlas data presented at EADV 2026 showed higher rates of complete and near-complete skin clearance with zasocitinib compared with deucravacitinib.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.
Advertisement
Advertisement
Trending on Dermatology Times
1
Icotrokinra Sustains Skin Clearance at High-Impact Psoriasis Sites Through 2 Years
2
EADV 2026 Day 3: Long-Term Psoriasis Data and Emerging Therapeutic Targets Take Focus
3
Ritlecitinib Improves Repigmentation in Nonsegmental Vitiligo
4
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
5